Panagiotis Iliakis: The ANDAMAN Trial and the Challenge of Aspirin Resistance
Panagiotis Iliakis, Interventional Cardiology and Research Fellow at Knappschaft Kliniken Universitätsklinikum Bochum, Fellow of European Society of Hypertension (FESH) at ESH, shared a post on LinkedIn:
”European Society of Cardiology – Working Group on Thrombosis
Paper of the Month
Aspirin dosing after acute coronary syndrome in patients with suspected aspirin resistance – insights from the ANDAMAN trial
Panagiotis Iliakis Dario Bongiovanni Diana Gorog Bruna Gigante
In our recent ESC WG on Thrombosis comment, we provide a critical appraisal of the ANDAMAN trial, recently published in the European Heart Journal, evaluating twice-daily versus once-daily aspirin dosing in patients with acute coronary syndrome and suspected aspirin resistance.
Can intensified aspirin dosing improve outcomes in high-risk ACS patients with enhanced platelet turnover, such as those with diabetes or obesity?
Despite a strong pharmacological rationale, twice-daily aspirin did not significantly reduce major adverse cardiovascular events compared with standard once-daily dosing.
The trial highlights the complex relationship between platelet inhibition and clinical outcomes, emphasizing that improved pharmacodynamic profiles do not always translate into improved prognosis.
These findings support current guideline-based aspirin strategies while underscoring the need for more individualized antithrombotic approaches in selected high-risk populations.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers